跳至主要内容
临床试验/ISRCTN29234515
ISRCTN29234515已完成未知

Ethinyloestradiol-Levonorgestrel versus Low-Dose Spironolactone-Pioglitazone-Metformin (SPIOMET) for Adolescent Girls with Polycystic Ovary Syndrome: On-Treatment and Post-Treatment Observations.

Hospital Sant Joan de Deu0 个研究点目标入组 42 人开始时间: 2012年8月8日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
42

研究概览

简要总结

2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/28712591 (added 29/01/2019) 2021 results in https://pubmed.ncbi.nlm.nih.gov/33782413/ (added 31/03/2021)

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • As of 21/07/2016:
  • 1. Clinical androgen excess (hirsutism) and/or biochemical hyperandrogenismwith or without biochemical androgen excess
  • 2. Chronological age between 14.0-17.9 years at study start
  • 3. Gynecological age (= time post-menarche) >2.0 years at study start
  • 4. Absence of sexual activity (intercourse)
  • 1.Clinical and biochemical hyperandrogenism
  • 2. Hyperinsulinemia (fasting and/or after an oGTT)
  • 3. Age >14 and >18 year
  • 4. Menarche at least 2 years before
  • 5. BMI <97th percentile and >10th percentile

排除标准

  • As of 21/07/2016:
  • 1. Evidence for adrenal hyperplasia, Cushing syndrome, hypothyroidism
  • 2. Evidence for lLiver or kidney dysfunction, diabetes, glucose intolerance
  • 3. Treatment with oral contraceptives, antiandrogens, or insulin sensitizers in past 6 months
  • 1. Pregnancy or pregnancy risk
  • 2. Late onset congenital adrenal hyperplasia, Cushing's syndrome, uncompensated hypothyroidism
  • 3. Liver or renal dysfunction, diabetes, glucose intolerance
  • 4. Treatment with oral contraceptives, antiandrogens, or insulin sensitizers over the previous 6 months
  • 5. Severe bacterial infections

研究者

相似试验